Literature DB >> 34563688

Right predominant electrical remodeling in a pure model of pulmonary hypertension promotes reentrant arrhythmias.

Benjamin Strauss1, Malik Bisserier2, Emerson Obus2, Michael G Katz2, Anthony Fargnoli2, Marine Cacheux3, Joseph G Akar3, James P Hummel3, Lahouaria Hadri2, Yassine Sassi4, Fadi G Akar5.   

Abstract

BACKGROUND: Electrophysiological (EP) properties have been studied mainly in the monocrotaline model of pulmonary arterial hypertension (PAH). Findings are confounded by major extrapulmonary toxicities, which preclude the ability to draw definitive conclusions regarding the role of PAH per se in EP remodeling.
OBJECTIVE: The purpose of this study was to investigate the EP substrate and arrhythmic vulnerability of a new model of PAH that avoids extracardiopulmonary toxicities.
METHODS: Sprague-Dawley rats underwent left pneumonectomy (Pn) followed by injection of the vascular endothelial growth factor inhibitor Sugen-5416 (Su/Pn). Five weeks later, cardiac magnetic resonance imaging was performed in vivo, optical action potential (AP) mapping ex vivo, and molecular analyses in vitro.
RESULTS: Su/Pn rats exhibited right ventricular (RV) hypertrophy and were highly prone to pacing-induced ventricular tachycardia/fibrillation (VT/VF). Underlying this susceptibility was disproportionate RV-sided prolongation of AP duration, which promoted formation of right-sided AP alternans at physiological rates. While propagation was impaired at all rates in Su/Pn rats, the extent of conduction slowing was most severe immediately before the emergence of interventricular lines of block and onset of VT/VF. Measurement of the cardiac wavelength revealed a decrease in Su/Pn relative to control. Nav1.5 and total connexin 43 expression was not altered, while connexin 43 phosphorylation was decreased in PAH. Col1a1 and Col3a1 transcripts were upregulated coinciding with myocardial fibrosis. Once generated, VT/VF was sustained by multiple reentrant circuits with a lower frequency of RV activation due to wavebreak formation.
CONCLUSION: In this pure model of PAH, we document RV-predominant remodeling that promotes multiwavelet reentry underlying VT. The Su/Pn model represents a severe form of PAH that allows the study of EP properties without the confounding influence of extrapulmonary toxicity.
Copyright © 2021 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Arrhythmias; Pneumonectomy; Pulmonary arterial hypertension; Remodeling; Right ventricular failure

Mesh:

Substances:

Year:  2021        PMID: 34563688      PMCID: PMC8742785          DOI: 10.1016/j.hrthm.2021.09.021

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.779


  27 in total

Review 1.  The monocrotaline model of pulmonary hypertension in perspective.

Authors:  Jose G Gomez-Arroyo; Laszlo Farkas; Aysar A Alhussaini; Daniela Farkas; Donatas Kraskauskas; Norbert F Voelkel; Harm J Bogaard
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-09-30       Impact factor: 5.464

2.  The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.

Authors:  D B Mendel; R E Schreck; D C West; G Li; L M Strawn; S S Tanciongco; S Vasile; L K Shawver; J M Cherrington
Journal:  Clin Cancer Res       Date:  2000-12       Impact factor: 12.531

3.  Cardiac arrhythmia mechanisms in rats with heart failure induced by pulmonary hypertension.

Authors:  David Benoist; Rachel Stones; Mark J Drinkhill; Alan P Benson; Zhaokang Yang; Cecile Cassan; Stephen H Gilbert; David A Saint; Olivier Cazorla; Derek S Steele; Olivier Bernus; Ed White
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-03-16       Impact factor: 4.733

4.  Microvolt T-wave alternans profile in patients with pulmonary arterial hypertension.

Authors:  Ewa Lewicka; Ludmiła Daniłowicz-Szymanowicz; Alicja Dąbrowska-Kugacka; Bożena Zięba; Paweł Zagożdżon; Grzegorz Raczak
Journal:  Int J Cardiol       Date:  2014-08-05       Impact factor: 4.164

5.  Bioactivation of monocrotaline by P-450 3A in rat liver.

Authors:  Y Kasahara; K Kiyatake; K Tatsumi; K Sugito; I Kakusaka; S Yamagata; S Ohmori; M Kitada; T Kuriyama
Journal:  J Cardiovasc Pharmacol       Date:  1997-07       Impact factor: 3.105

6.  Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization.

Authors:  Shiro Mizuno; Laszlo Farkas; Aysar Al Husseini; Daniela Farkas; Jose Gomez-Arroyo; Donatas Kraskauskas; Mark R Nicolls; Carlyne D Cool; Herman J Bogaard; Norbert F Voelkel
Journal:  Am J Respir Cell Mol Biol       Date:  2012-07-27       Impact factor: 6.914

Review 7.  Activation and pulmonary toxicity of pyrrolizidine alkaloids.

Authors:  R J Huxtable
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

Review 8.  Arrhythmias in pulmonary arterial hypertension.

Authors:  Archana Rajdev; Hasan Garan; Angelo Biviano
Journal:  Prog Cardiovasc Dis       Date:  2012 Sep-Oct       Impact factor: 8.194

9.  Microvolt T-wave alternans profiles in patients with pulmonary arterial hypertension compared to patients with left ventricular systolic dysfunction and a group of healthy volunteers.

Authors:  Ludmila Danilowicz-Szymanowicz; Ewa Lewicka; Alicja Dabrowska-Kugacka; Agnieszka Niemirycz-Makurat; Joanna Kwiatkowska; Zuzanna Lewicka-Potocka; Katarzyna Rozwadowska; Emilia Stepnowska; Grzegorz Raczak
Journal:  Anatol J Cardiol       Date:  2016-04-07       Impact factor: 1.596

10.  Systems approach to the study of stretch and arrhythmias in right ventricular failure induced in rats by monocrotaline.

Authors:  David Benoist; Rachel Stones; Alan P Benson; Ewan D Fowler; Mark J Drinkhill; Matthew E L Hardy; David A Saint; Olivier Cazorla; Olivier Bernus; Ed White
Journal:  Prog Biophys Mol Biol       Date:  2014-07-09       Impact factor: 3.667

View more
  3 in total

1.  Dapagliflozin reduces the vulnerability of rats with pulmonary arterial hypertension-induced right heart failure to ventricular arrhythmia by restoring calcium handling.

Authors:  Jinchun Wu; Tao Liu; Shaobo Shi; Zhixing Fan; Roddy Hiram; Feng Xiong; Bo Cui; Xiaoling Su; Rong Chang; Wei Zhang; Min Yan; Yanhong Tang; He Huang; Gang Wu; Congxin Huang
Journal:  Cardiovasc Diabetol       Date:  2022-09-28       Impact factor: 8.949

2.  Experimental animal models of pulmonary hypertension: Development and challenges.

Authors:  Xiao-Han Wu; Jie-Ling Ma; Dong Ding; Yue-Jiao Ma; Yun-Peng Wei; Zhi-Cheng Jing
Journal:  Animal Model Exp Med       Date:  2022-03-25

Review 3.  Novel Insights into the Therapeutic Potential of Lung-Targeted Gene Transfer in the Most Common Respiratory Diseases.

Authors:  Malik Bisserier; Xiao-Qing Sun; Shahood Fazal; Irene C Turnbull; Sébastien Bonnet; Lahouaria Hadri
Journal:  Cells       Date:  2022-03-12       Impact factor: 7.666

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.